J. Safra Sarasin Holding AG Has $870,000 Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Key Points

• J. Safra Sarasin Holding AG reduced its holdings in IDEXX Laboratories by 16.9%, owning 2,072 shares valued at approximately $870,000 as of the end of the last quarter.
• IDEXX Laboratories reported a $3.63 EPS for the last quarter, surpassing expectations by $0.35, with revenues increasing by 10.6% year-over-year to $1.11 billion.
• Analysts have raised their price targets for IDEXX Laboratories, with a consensus target of $570.38 and ratings suggesting a "Moderate Buy."

J. Safra Sarasin Holding AG decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 16.9% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,072 shares of the company's stock after selling 421 shares during the quarter. J. Safra Sarasin Holding AG's holdings in IDEXX Laboratories were worth $870,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. MorganRosel Wealth Management LLC bought a new stake in IDEXX Laboratories during the first quarter valued at $26,000. Colonial Trust Co SC raised its stake in IDEXX Laboratories by 84.8% during the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after acquiring an additional 39 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in IDEXX Laboratories by 55.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock worth $35,000 after acquiring an additional 30 shares during the last quarter. Bank of Jackson Hole Trust boosted its stake in IDEXX Laboratories by 328.6% in the first quarter. Bank of Jackson Hole Trust now owns 90 shares of the company's stock valued at $39,000 after acquiring an additional 69 shares during the period. Finally, Itau Unibanco Holding S.A. boosted its stake in IDEXX Laboratories by 540.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after acquiring an additional 81 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently commented on IDXX. Morgan Stanley set a $722.00 target price on IDEXX Laboratories and gave the company an "overweight" rating in a research report on Tuesday. Jefferies Financial Group began coverage on shares of IDEXX Laboratories in a report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price objective for the company. Wall Street Zen upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Saturday, July 12th. Stifel Nicolaus set a $640.00 price objective on shares of IDEXX Laboratories in a report on Monday. Finally, JPMorgan Chase & Co. upped their target price on IDEXX Laboratories from $550.00 to $675.00 and gave the stock an "overweight" rating in a research report on Monday. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $623.56.

Insider Buying and Selling

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the firm's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the sale, the director owned 1,801 shares in the company, valued at approximately $922,724.34. This trade represents a 41.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.98% of the company's stock.

IDEXX Laboratories Stock Performance

IDXX stock traded down $17.75 on Wednesday, reaching $624.19. 816,294 shares of the company were exchanged, compared to its average volume of 770,026. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.81. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $688.12. The stock's fifty day moving average price is $537.43 and its 200 day moving average price is $475.11. The firm has a market capitalization of $50.20 billion, a PE ratio of 51.97, a PEG ratio of 4.32 and a beta of 1.49.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping analysts' consensus estimates of $3.28 by $0.35. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The firm's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period last year, the firm earned $2.44 EPS. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.